COVID-19. COVID-19
Conditions
Interventions
Intervention 1: vitamin D supplement (two 50,000 IU capsules at the beginning of the study, two 50,000 IU capsules on the 4th day, one 50,000 IU capsule on the 11th day, and one 50,000 IU capsule on t
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: People aged 18-65 confirmation of Covid-19 infection by RT-PCR test completing informed consent less than 48 hours have passed since the patient was hospitalized no skin or gastrointestinal allergies due to taking multivitamin supplements, vitamin D, and magnesium people with more than 30 breaths per minute and less than 93% oxygen saturation in room air and sea level.
Exclusion criteria
Exclusion criteria: Pregnancy or lactation take a daily multivitamin or take a vitamin D or magnesium supplement in the last month participating in other clinical studies renal failure or dialysis, severe liver disease or cirrhosis known diagnosis of hypercalcemia patients who discharged from the hospital less than 24 hours after the start of the intervention history of kidney stones in the last year transfer the patient to the ICU baseline vitamin D levels above 80 ng/ml baseline magnesium levels above 2.6 mg/dl.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myalgia. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: to be or not to be.;Fever. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: to be or not to be.;Dry cough. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: to be or not to be.;Shortness of breath. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: to be or not to be.;Percentage of oxygen saturation. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: Oxygen meter.;WBC. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: Laboratory tests.;CRP. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: Laboratory tests.;MDA. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: Laboratory tests.;TAC. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: Laboratory tests.;Headache. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: to be or not to be.;Mortality. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: number.;Neutrophil count. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: number.;Lymphocyte count. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: number.;The ratio of neutrophils to lymphocytes. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: Percentage.;25 hydroxyvitamin D. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: Nanograms per milliliter.;Magnesium. Timepoint: at baseline and at the end of study (3 weeks later). Method of measurement: milligram per deciliter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNahid Ramezani-Jolfaie
Bandare-abbas University of Medical Sciences
Outcome results
None listed